Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Kineta is raising $27,297,815.00 in new funding. Sources indicate as part of senior management President, Craig Philips played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kineta
Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients lives. Since our inception, our focus has been targeting novel innate immune pathways where the biology had not yet translated into innovative therapies. We have leveraged our expertise in innate immunity to discover and develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. One of Kinetas key competitive advantages was building a strong foundation with an industry-leading scientific team who drive our research and development engine bolstered by an exceptional immuno-oncology focused scientific advisory board. We have integrated strong commercial leadership with our research and development team to enable Kineta to advance multiple drug programs in areas with high unmet needs and significant commercial potential.

To learn more about Kineta, visit http://www.kinetabio.com/

Contact:
Craig Philips, President
206-378-0400
cphilips@kinetabio.com
https://www.linkedin.com/in/craigphilips/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved